Patents by Inventor Jingchuan Zhang

Jingchuan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA
    Publication number: 20240358703
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: January 19, 2024
    Publication date: October 31, 2024
    Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG
  • ERK1/2 AND EGFR INHIBITORS COMBINATION THERAPY
    Publication number: 20240307392
    Abstract: The present disclosure relates generally to the use of an ERK1/2 inhibitor in combination with a EGFR inhibitor for treating cancer, specifically solid tumors. The present disclosure also relates to the use of an ERK 1/2 inhibitor in combination with a EGFR inhibitor and a BRAF inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 19, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Leslie Harris BRAIL, Leenus MARTIN, Jingchuan ZHANG, Joanne OH
  • ERK1/2 AND SHP2 INHIBITORS COMBINATION THERAPY
    Publication number: 20240299388
    Abstract: The present disclosure relates generally to the use an ERK1/2 inhibitor in combination with a SHP2 inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 12, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Leslie Harris BRAIL, Leenus MARTIN, Jingchuan ZHANG, Joanne OH
  • ERK1/2 OR SHP2 INHIBITORS AND FLT3 INHIBITORS COMBINATION THERAPY
    Publication number: 20240285624
    Abstract: The present disclosure relates generally to the use of an ERK1/2 inhibitor or a SHP2 inhibitor in combination with a FLT3 inhibitor, such as gilteritinib, for treating cancer, specifically acute myeloid leukemia (AML).
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Inventors: Robert Field SHOEMAKER, Wei LIN, Erin Denise LEW, Jingchuan ZHANG, Joanne OH, Leenus MARTIN, Leslie Harris BRAIL
  • ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY
    Publication number: 20240285625
    Abstract: The present disclosure relates generally to the use of an ERK 1/2 inhibitor in combination with a KRAS G12C inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Jingchuan ZHANG, Joanne OH
  • Methods for treating hematological malignancies and Ewing's sarcoma
    Patent number: 11944627
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 2, 2024
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Francis Burrows, Linda V. Kessler, Liansheng Li, Pingda Ren, Yi Wang, Tao Wu, Jingchuan Zhang
  • METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA
    Publication number: 20230026872
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 26, 2023
    Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG, I
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 9221915
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: December 29, 2015
    Assignees: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1
    Publication number: 20120052074
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 1, 2012
    Applicants: PFIZER INC., AMGEN FREMONT INC.
    Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 8080646
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: December 20, 2011
    Assignees: Amgen Fremont, Inc., Pfizer Inc.
    Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelly Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1
    Publication number: 20100197005
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: March 12, 2009
    Publication date: August 5, 2010
    Applicants: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Shelley Sims Belouski, Sirid-Aimee Kellermann, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 7537762
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: May 26, 2009
    Assignees: Amgen Fremont, Inc., Pfizer Inc.
    Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Publication number: 20070065444
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 22, 2007
    Applicants: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Michael North, Karin Amundson, Vahe Bedian, Shelley Belouski, Dana Hu-Lowe, Xin Jiang, Shannon Karlicek, Sirid Kellermann, James Thomson, Jianying Wang, Grant Wickman, Jingchuan Zhang